Caricamento...
Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
PURPOSE: To determine tolerability and for the first time explore efficacy of bendamustine plus rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using 2 different dose levels of bendamustine. EXPERIMENTAL DESIGN: HCL patients with ≥2 prior therapies requiring treatment recei...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3861900/ https://ncbi.nlm.nih.gov/pubmed/24097860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1848 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|